A disappointing directive issued recently by the federal government demonstrates the antiquated fashion in which the United States approaches marijuana laws.
Responding to a request delivered in 2011 by then-Washington Gov. Chris Gregoire, officials announced that marijuana would remain on the government’s list of Schedule I drugs, indicating that there is “no accepted medical use” for cannabis. This likely comes as a surprise to the millions of people across the country who have found that marijuana can ease symptoms for disorders such as epilepsy, post-traumatic stress disorder, and multiple sclerosis. Some 25 states have approved the drug for medical use.
But, in a classic Catch-22 of bureaucracy, the Obama administration said there is no scientific proof of these benefits — because there has been a dearth of scientific research. For years, the federal government has limited scientific examination of the issue by designating one small facility at the University of Mississippi as the only acceptable grower of research-grade marijuana. The message to proponents of marijuana for medical or recreational use: “You can’t research the drug because we won’t allow you to grow it, and you can’t prove its benefits because there is little research.”
With marijuana remaining on the list of Schedule I drugs, it is lumped into a category with heroin and LSD. It is not difficult to build an argument that marijuana is more beneficial and less dangerous than those drugs, but decades of failed drug policy have hampered the establishment of proof to that end. “We will remain tethered to science, as we must and as the statute demands,” said Chuck Rosenberg, acting administrator of the Drug Enforcement Agency. “It certainly would be odd to rely on science when it suits us and ignore it otherwise.”